|
Indian Pediatr 2019;56: 959-964 |
|
Liberal vs. Conservative Approach to
Timing of Blood Transfusion in Severely Anemic Children
|
Source Citation: Maitland K, Kiguli S,
Olupot-Olupot P, Engoru C, Mallewa M, Saramago Goncalves P, et al.
Immediate transfusion in African children with uncomplicated severe
anemia. N Engl J Med. 2019;381:407-19.
Section Editor: Abhijeet Saha
|
Summary
In this open label trial, children aged 2 months to
12 years with uncomplicated severe anemia received immediate blood
transfusion in the intervention group while in the control group,
immediate transfusion was withheld. Children in the intervention group
were further randomized to receive higher (30 mL/kg whole blood/ 15 mL/kg
packed cells) or lower (20 mL/kg whole blood/ 10 mL/kg packed cells)
volume, administered immediately after enrolment. Hemoglobin (Hb) was
measured 8-hourly, and an additional transfusion using the original
volume was given if the criteria for transfusion were met. For children
requiring further transfusions, only 20 mL/kg whole blood (or 10 mL/kg
packed cells) was used. In the control group, transfusion with 20 mL/kg
of whole-blood equivalent was triggered by new signs of clinical
severity or a drop in Hb to below 4 g/dL during 8-hourly monitoring, The
primary out-come was 28-day mortality. Three other randomizations
investigated transfusion volume, post-discharge supplementation with
micronutrients, and post-discharge prophylaxis with
trimethoprim–sulfamethoxazole.
A total of 1565 children underwent randomization,
with 778 assigned to the immediate-transfusion group and 787 to the
control group. The children were followed for 180 days, and 71 (4.5%)
were lost to follow-up. During the primary hospitalization, transfusion
was performed in all the children in the immediate-transfusion group and
in 386 (49%) in the control group (median time to transfusion, 1.3 hours
vs. 24.9 hours). The mean (SD) total blood volume transfused per
child was 314 (228) mL in the immediate transfusion group, and 142 (224)
mL in the control group. Seven children (0.9%) in the
immediate-transfusion group and 13 (1.7%) in the control group died by
28 days (HR 0.54; 95% CI 0.22, 1.36; P=0.19), and 35 (4.5%) and
47 (6.0%), respectively (HR 0.75; 95% CI, 0.48, 1.15) by 180 days,
without evidence of interaction with other randomizations or evidence of
between-group differences in readmissions, serious adverse events, or
hemoglobin recovery at 180 days. The authors concluded that there was no
evidence of differences in clinical outcomes over 6 months between the
children who received immediate transfusion and those who did not.
Commentaries
Evidence-based Medicine Viewpoint
Relevance: Severe anemia (defined as hemoglobin
less than 6 g/dL), is a frequent cause of childhood hospitalization in
many African countries [1,2]. The traditional approach in such children
is to offer blood transfusion only if hemoglobin (Hb) is less than 4 g/dL,
or when Hb is 4-6 g/dL in the presence of clinical features like
dehydration, shock, altered sensorium, cardiac failure, breathing
difficulty, hemoglobinuria, or underlying sickle cell disease. This
somewhat conservative approach is based on the World Health Organization
(WHO) recommendations [3], which are based on dated observational
studies with methodological limitations. This randomized clinical trial
[4] compared a liberal (i.e., immediate blood transfusion)
versus conservative (i.e., as per WHO guidelines) approach in
children with uncomplicated severe anemia (defined as mentioned above).
Table I outlines the characteristics of the trial [1].
TABLE I Outline of the Trial
Parameter |
Comments |
Clinical question |
Although a clinical question in the traditional PICOT format was
not mentioned, it could be stated as: “In children with severe
uncomplicated anemia (Hb 4-6 g/dL) without signs of clinical
severity (P=Population), what is the efficacy, safety and cost
(O=Outcomes) of immediate blood transfusion (I=Intervention)
compared to no immediate transfusion (C=Comparison) over a
period of 6 months (T=Time frame)?” |
Study design |
Randomized controlled trial with individual participants
randomized 1:1 to two groups viz immediate transfusion versus no
immediate transfusion. The former were further randomized to
receive either 20 mL/kg or 30mL/kg of whole-blood equivalent.
|
Study setting |
Three hospitals in Uganda and one hospital in Malawi.
|
Study duration
|
September 2014 to May 2017. |
Inclusion criteria |
Children (2 mo to 12 y) admitted with ‘severe uncomplicated
anemia’, defined as Hb 4-6 g/dL without signs of clinical
severity (altered sensorium, respiratory distress, or acute
hemoglobinuria) or pre-existing sickle cell disease.
|
Exclusion criteria |
Children with prior renal or hepatic failure, malignancy,
congenital cardiac defect, trauma/burns, or those requiring
surgical intervention. Exclusively breastfed babies were
excluded without explanation. |
Intervention and
Comparison groups |
Intervention: higher (30 mL/kg whole blood/ 15 mL/kg packed
cells) or lower (20 mL/kg whole blood/ 10 mL/kg packed cells)
volume, administered immediately after enrolment. Control:
transfusion (20 mL/kg whole blood/ 10 mL/kg packed cells) only
if Hb dropped below 4 g/dL and/or they developed clinical signs
of severity. |
Outcomes |
Primary: Death occurring within 28 days after randomization.
Secondary: death within 48 h, 90 days or 180 days of
randomization; proportion in whom Hb declined <4 g/dL during
admission; proportion in whom Hb declined <6 g/dL after
discharge; proportion in whom Hb increased >9 g/dL (although
time point of measurement was not specified); proportion
re-hospitalized; number developing transfusion reactions; number
developing serious adverse events; cost of management;
cost-effectiveness. |
Follow-up protocol |
Clinical examination was done at baseline (randomization), 30
min, 1 h, 90 min, 2 h, 4 h, 8 h, 16 h, 24 h, and 48 h. The
parameters evaluated were not specified. Hb was measured at 8 h,
16 h, 24 h, 48 h, and additionally if there was (undefined)
clinical worsening. Clinical and Hb examination were done
after discharge on days 28, 90 and 180. |
Sample size |
A
priori sample size calculation was performed for a superiority
trial, to detect 50% decline in 28-day mortality from an
expected baseline 9% to 4.5%. Allowance was made for an
attrition rate of 6%. |
Data analysis |
Intention-to-treat (ITT) analysis was undertaken, analyzing
participants in the same groups to which they were randomized.
However, the outcome assignment to drop-outs was not specified.
|
Comparison of groups at
baseline |
The
groups were comparable at baseline with respect to median age,
gender, anthropometric measurements, clinical features (vital
signs, fever, signs of shock/dehydration), laboratory parameters
(proportion with HIV, malaria, positive blood culture, CRP and
lactate level). Proportions with previous transfusions and
underlying sickle cell disease were also calculated. In
addition, after the trial was completed, genotyping was
undertaken to identify unknown sickle cell disease. |
Summary of results
(Intervention vs
Comparison groups) |
Primary outcome: |
•
Death occurring within 28 d : 7/778 vs 13/787; OR 0.54 (CI 0.22,
1.36) |
Secondary outcomes: |
•
Death within 48 h: 0/778 vs 2/787; OR 0.20 (CI 0.01, 4.21) |
•
Death within 90 d: 24/778 vs 31/787; OR 0.78 (CI 0.45, 1.33) |
•
Death within 180 d: 35/778 vs 47/787; OR 0.74 (CI 0.47, 1.16) |
•
Proportion in whom Hb declined <4 g/dL during hospitalization:
11/778 vs 309/787; OR 0.03 (CI 0.02, 0.05) |
•
Proportion in whom Hb declined <6 g/dL after discharge: 106/778
vs 142/787; OR 0.73 (0.56, 0.94) |
•
Proportion in whom Hb increased >9 g/dL: 399/778 vs 43/787; OR
11.73 CI 8.69, 15.84) |
• Proportion
re-hospitalized: 123/778 vs 113/787; OR 1.09 (CI 0.84, 1.40) |
•
Number developing transfusion reactions: 0/778 vs 0/787; OR 1.0
(CI 0.02, 51.05) |
•
Number of allergic reactions: 6 vs 2 (but no. of children not
specified) |
•
Cost of management: USD 72.1 vs USD 66.5 |
•
Cost-effectiveness: Incremental cost-effectiveness ratio (ICER)
not presented. However, the life years gained over 6 months were
not different in the two groups. |
Critical appraisal: Table II
outlines the methodological aspects of the trial. Overall, the
methodological quality was high. The trial protocol was published [5],
and there are no deviations discernible. However, some points require
careful consideration.
Table II Critical Appraisal of Trial Methodology
Criteria |
Conclusion |
Comments |
Generation of random sequence |
Adequate. |
The
sequence (to allocate participants into the immediate versus no
immediate transfusion groups) was generated using a computer
program; although, details were not provided. Variable block
sizes were used though the range of block sizes was not
mentioned. The method for further randomizing those in the
immediate transfusion groups to higher or lower transfusion
volumes was not mentioned. |
Allocation concealment |
Adequate |
Opaque, sealed envelopes contained the main allocation. However,
the method for concealing the subsequent randomization to higher
or lower transfusion volumes was not mentioned. |
Blinding |
Inadequate |
Clinicians evaluating clinical outcomes were unblinded. Although
the investigators reported that the laboratory tests were
performed in a blinded fashion, this seems unlikely as Hb was
done at the bedside. The participants/family members were not
blinded. |
Completeness of reporting |
Adequate |
All
randomized participants were included in the primary
intention-to-treat analysis. The required sample size was
fulfilled for this. Detailed description of participants who
dropped out were provided. However, cost-effectiveness was not
formally calculated. |
Selectiveness of outcome reporting |
Adequate |
Almost all relevant outcomes (clinical and lab) were reported.
|
Overall impression |
Low
risk of bias |
|
In this trial [4], the mortality rate in both arms
was far lower than the anticipated baseline mortality rate of 9%. Thus,
although there was approximately 50% lower mortality in the intervention
arm (0.9% compared to 1.7%), the trial remained underpowered to confirm
if a true difference existed. The investigators acknowledged this issue,
explaining that screening of children for possible enrolment in the
trial was ceased when blood was unavailable for transfusion. Although
this is a reasonable explanation, it raises the problem of logistic
feasibility. Even if immediate transfusion had been superior, it seems
unlikely that eligible children could/would get transfused on account of
limited supplies of blood. This gap between research and practice needs
to be addressed before the research findings could be implemented.
The investigators did not report the cause of severe
anemia in the enrolled children. Although it could be argued that this
may not affect the internal validity of the study, it is important to
determine comparability between the study arms. It is also interesting
to wonder how/why children with Hb <6 g/dL were relatively stable. This
suggests that they were suffering from chronic anemia related to
underlying disease, since severe malnutrition was present in very few
(<4%) enrolled children. This is also borne by the fact that after the
study, sickle cell disease was confirmed in a significant proportion of
the children. Further, it appears that three-quarters of the control
group children who received transfusion had a drop in Hb while under
observation, suggesting ongoing blood loss or hemolysis, neither of
which were investigated further. It is also somewhat unusual that nearly
a quarter of the children had received transfusion prior to the current
illness, yet were not investigated further.
The WHO clinical practice guidelines for medical
interns [6] prescribes 5 mL/kg of packed cells or 10 mL/kg whole blood
in children with severe uncomplicated anemia; although, the handbook
prescribes larger volume [3]. The first transfusion is recommended
rapidly to restore oxygen carrying capacity, whereas subsequent
transfusions (if required.) should not exceed 5 mL/kg/h. Oral or
intravenous frusemide in the dose 1 mg/kg is mentioned if there is
likelihood of circulatory overload. The transfusion protocol used in
this trial [4] was not described; hence, the rate of transfusion and
duration cannot be ascertained. This is especially important considering
that not a single one of over 1000 transfused children developed
transfusion-related fluid overload or lung injury, despite the
deliberate avoidance of frusemide midway. Similarly, only eight children
had an allergic reaction. These impressive findings beg for more data on
how this was achieved.
In the majority of resource-limited settings,
especially sub-Saharan Africa, most blood transfusions are administered
as whole blood. In contrast, developed healthcare systems prefer
component transfusions with packed red cells [7,8]. This is related to
potential circulatory overload with whole blood, and benefit of use in
multiple patients when components are used. However, there are logistic
challenges to fractionate blood in most developing country settings. A
recent systematic review [9] examined 14 national transfusion practice
guidelines published in African countries. Among those covering the
pediatric age group, three recommended transfusing packed cells, whereas
two permitted either to be used. However, none of these guidelines
provided a basis for the recommendation. It appears that although
component transfusion is preferred despite the lack of robust supporting
evidence, it is often logistically infeasible. The issue is important in
this trial [4] because facilities existed for both whole blood as well
as packed cell transfusion. In fact, almost half the children transfused
(in either group) received packed cells. However, the basis for deciding
which individual child would receive whole blood (versus packed
cells) was not clarified. The investigators have not reported subgroup
analysis to judge the relative efficacy and safety, within as well as
between groups.
Although the trial showed a distinct inter-group
difference in Hb level during the first 48 hours, the gap narrowed to
clinically insignificant values at the follow-up visits on days 28, 90
and 180. Unfortunately, the figures in the publication [4] did not
clarify whether this happened only to transfused control group children,
or to all in the control group. There is also no ready explanation about
why the transfused children showed increase in Hb from around 5 g/dL at
48 hours to nearly 9 g/dL by day 180.
The investigators reported a statistically
significant difference in the overall duration of hospital stay between
the groups, with a day less hospitalization in those who were transfused
immediately. However, this outcome was not specified a priori,
and appears to a post hoc analysis. The investigators did not
compare the outcomes among those receiving higher versus lower
transfusion volume in the immediate transfusion group; hence, this
aspect cannot be appraised.
Although cost-effectiveness was expected to be
reported, the investigators undertook a cost minimization exercise,
showing that the total cost of conventional transfusion was
approximately USD 5.6 less than the cost of immediate transfusion.
Calculation of the incremental cost-effectiveness ratio (ICER) would
have been more useful. But since the gain in life years was the same in
both groups, the analysis would have favored the conservative approach.
In terms of costs, it is intriguing that mean cost of hospitalization
over 4-5 days was merely (approximately) USD 30. This is especially
remarkable considering the sickness level of the children, and that
almost two-thirds had malaria. It is even more remarkable considering
that the costs of measuring Hb 5 times during hospitalization was
approximately one-third as much as the total hospitalization cost. These
observations suggest that the actual cost of hospitalization may have
been higher than represented, thereby widening the gap between the two
groups.
Extendibility and Conclusion: This trial
did not find overall benefit of immediate blood transfusion over
traditional conservative approach. However, there are several
methodological issues requiring clarification, to understand the true
value of this study. There are several major differences from the trial
setting and the Indian setting. These include the relatively high burden
of uncomplicated severe anemia in sub-Saharan Africa, underlying causes
of severe anemia (chronic disease with a high burden of malaria, but
relatively uncommon severe malnutrition), underlying sickle cell disease
in a significant proportion, and management protocols to pragmatically
manage severe anemia in children. In India, the National Family Health
Survey-4 [10] used a cut-off of 11 g/dL to identify anemia in over half
of the children younger than 5 years, highlighting the stark difference
from sub-Saharan Africa. Further, most hospital protocols in Asian
countries correct anemia below 7 g/dL using packed cells, with careful
monitoring and interventions to prevent fluid overload [11]. For these
reasons, the findings in this trial [4] may not be directly applicable
to Indian context.
Funding: None; Competing interests: None
stated.
Joseph L Mathew
Department of Pediatrics,
PGIMER, Chandigarh, India.
Email:
[email protected]
References
1. Kiguli S, Maitland K, George EC, Olupot-Olupot P,
Opoka RO, Engoru C, et al. Anaemia and blood transfusion in
African children presenting to hospital with severe febrile illness. BMC
Med. 2015;13:21.
2. Opoka RO, Ssemata AS, Oyang W, Nambuya H, John CC,
Tumwine JK, et al. High rate of inappropriate blood transfusions
in the management of children with severe anemia in Ugandan hospitals.
BMC Health Serv Res. 2018;18:566.
3. World Health Organization. Pocket Book of Hospital
Care for Children: Guidelines for the Management of Common Childhood
Illnesses. 2nd ed. 2013. Available from: https://books.google.co.in/books?hl=en&lr=&id=FLEXDAAA
QBAJ&oi=fnd&pg=PP1&ots=4PjQU619dg&sig=
t19Ob9T5ZYKwWtaIlwBHv1WtbYo&redir_esc=y#v= onepage&q=transfusion&f=false.
Accessed October 12, 2019.
4. Maitland K, Kiguli S, Olupot-Olupot P, Engoru C,
Mallewa M, Saramago Goncalves P, et al. Immediate transfusion in
African children with uncomplicated severe anemia. N Engl J Med
2019;381:407-19.
5. Mpoya A, Kiguli S, Olupot-Olupot P, Opoka RO,
Engoru C, Mallewa M, et al. Transfusion and Treatment of severe
anemia in African children (TRACT): A study protocol for a randomized
controlled trial. Trials. 2015;16:593.
6. World Health Organization. Clinical Transfusion
Practice Guidelines for Medical Interns. Available from:
https://www.who.int/bloodsafety/transfusion_services/Clinical
TransfusionPracticeGuidelinesforMedicalInterns Bangladesh.pdf ?ua=1.
Accessed October 13, 2019.
7. New York State Council on Human Blood and
Transfusion Services: Blood and Tissue Resources Program 2016. Available
from: https://www.wadsworth. org/sites/default/files/WebDoc/ped_tx_
guidelines_2.pdf. Accessed October 13, 2019.
8. Lau W. Neonatal and Pediatric Transfusion.
Available from:https://professionaleducation.blood.ca/en/transfusion/guide-clinique/neonatal-and-pediatric-transfusion.
Accessed October 14, 2019.
9. Kohli N, Bhaumik S, Jagadesh S, Sales RK, Bates I.
Packed red cells versus whole blood transfusion for severe paediatric
anemia, pregnancy-related anemia and obstetric bleeding: an analysis of
clinical practice guidelines from sub-Saharan Africa and evidence
underpinning recommendations. Trop Med Int Health. 2019;24:11-22
10. National Family Health Survey, India. Key
Findings from NFHS-4. Available from: http://rchiips.org/nfhs/factsheet
_nfhs-4.shtml. Accessed October 14, 2019.
11. Ali N. Red blood cell transfusion in infants and
children- Current perspectives. Pediatr Neonatol. 2018;59:227-30.
Pediatrician’s
Viewpoint
The prevalence of childhood anemia in India has
remained high over the last few decades and as per NFHS-4 estimates, 58%
children under 5 years of age anemic and 2% have severe anemia [1].
Restrictive red blood cell (RBC) transfusion strategy at a hemoglobin
cut-off level of 7 g/dL has been advocated to reduce transfusion
requirements without significant increase in adverse effects [2].
In the current multicenter study, Maitland, et al.
[3] have demonstrated that immediate transfusion led to early hemoglobin
recovery than the triggered transfusion strategy, and also reduced the
number of children who developed profound anemia (Hb <4 g/dL) but the
hospital readmission rates did not differ in the two groups. In the
trial settings, clinical and Hb monitoring was an inbuilt component of
the treatment strategy, which is usually not possible rigorously in the
actual clinical and field settings. This also contributes significantly
to the associated mortality in these children.
Considering the fact that India still has a very high
prevalence of malnutrition and a large burden of children with severe
acute malnutrition [4], unlike that reported by Maitland et al.
[3], wherein it has been shown that early transfusion within the first
48 hours of admission has less adverse effects and mortality than RBC
transfusion later during the course of management, it seems prudent to
perform immediate transfusion in children with uncomplicated severe
anemia.
Despite the rigorous trial design, there were
patients lost to follow-up. In day-to-day clinical practice in the
resource constrained settings with patients coming from far off
distances, it is extremely difficult for the treating clinicians to
ensure follow-up, and it will be a challenge to closely monitor such
children with severe anemia who are discharged without transfusion and
may decompensate in the community setting.
In the current study, there is no mention of anti-helminthic
treatment received by any of the participants. In settings with a high
burden of helminthic and parasitic infestations, if left untreated,
anemia may recur, which may be a significant contributor to the
readmission rates to the hospital; the current study was not able to
find a difference in the readmission rate in the two groups.
Although, the immediate transfusion strategy may
overburden the blood bank resources, the benefits of improved survival
in children with severe anemia may outweigh this burden.
Funding: None; Competing interests: None
stated.
Bhavana Dhingra
Department of Pediatrics,
AIIMS, Bhopal, India.
Email:
[email protected]
References
1. Ministry of Health and Family Welfare.
International Institute for Population Sciences (IIPS) and ICF. 2017.
National Family Health Survey (NFHS-4), 2015-16: India. Mumbai: IIPS.
Available from: http://rchiips.org/nfhs/NFHS-4Reports/India.pdf.
Accessed October 23, 2019.
2. Lacroix J, Hébert PC, Hutchison JS, Hume HA, Tucci
M, Ducruet T, et al. Transfusion strategies for patients in
pediatric intensive care units. N Engl J Med. 2007;356:1609-19.
3. Maitland K, Kiguli S, Olupot-Olupot P, Engoru C,
Mallewa M, Saramago Goncalves P, et al. Immediate transfusion in
African children with uncomplicated severe anemia. N Engl J Med.
2019;381:407-19.
4. National Health Mission. Ministry of Health and
Family Welfare. Operational Guidelines for Facility-based Management of
Children with Severe Acute Malnutrition. 2011:India. Available from:
https://nhm.gov.in/index1. php?lang=1&level=3&sublinkid=1182&lid=364.
Accessed October 23, 2019.
|
|
|
|